CIP
XLRN

Convergence Investment Partners’s Acceleron Pharma XLRN Stock Holding History

Convergence Investment Partners’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,764
Closed -$149K – 334
2019
Q3 		$149K Buy
+3,764
New +$163K 0.04% 252
2014
Q2 		– Sell
-23,460
Closed -$809K – 439
2014
Q1 		$809K Buy
+23,460
New +$1.06M 0.12% 234

Other funds holding XLRN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Convergence Investment Partners's XLRN Position: Q4 2019 in Review

Convergence Investment Partners sold out of Acceleron Pharma (XLRN) in Q4 2019, closing a stake of 3,764 shares — an estimated $149K sold.

Convergence Investment Partners first reported a position in XLRN in Q1 2014 and held it in 2 quarters. The position peaked at $809K in Q1 2014. 183 funds tracked by Wall St. Rank hold XLRN as of Q4 2019.

  • Convergence Investment Partners reported no remaining Acceleron Pharma position as of Q4 2019 after selling out during the quarter.
  • Convergence Investment Partners sold 3,764 Acceleron Pharma shares in Q4 2019, an estimated $149K.
  • Convergence Investment Partners first reported a position in Acceleron Pharma in Q1 2014 and held it in 2 quarters.
  • Convergence Investment Partners's Acceleron Pharma position peaked at $809K in Q1 2014.
  • 183 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2019.

Based on Convergence Investment Partners's 13F filing for Q4 2019, filed 22 Jan 2020.